Brendan Guercio
@BrendanGuercio
Followers
354
Following
807
Media
18
Statuses
255
GU Oncologist at @UofR @WilmotCancer | Alumnus @MSKCancerCenter @BrighamMedRes @harvardmed | Views my own.
Joined July 2015
Incredibly grateful to @BladderCancerUS for the opportunity to define the impact of diet & microbiome to help patients w/ #bladdercancer. Thank you to project mentors @IyerGopa @LPeppone, advocate Rick Bangs, and collaboration of so many @tsonipeled @DrRosenbergMSK @PaulBarrMD.
Please join BCAN in congratulating the recipients of our 2024 Career Development Award, @anglayteng of @Stanford and @BrendanGuercio of @wilmotcancer. Both Drs. Ang and Guercio presented outstanding proposals that you can learn more about here:
4
3
38
RT @shilpaonc: An excellent session chaired by @siadaneshmand #GopaIyer on evolving strategies after EV-pembro in bladder cancer @BladderCa….
0
3
0
RT @chavarriagaj: At #BCANTT25, @BrendanGuercio spotlighted a novel modifiable factor in ICB response for metastatic UC: dietary fiber. 🔬….
0
4
0
Outstanding panel on clinical trials at #bcantt25 with fantastic pearls for investigators working hard on #bladdercancer . Only possible thanks to @BladderCancerUS !
0
5
15
RT @tompowles1: With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to….
0
75
0
RT @OncBrothers: That’s a wrap here in Buffalo, NY for 2nd Annual Upstate NY Cancer Symposium! Thank you to the local @RoswellPark, @Wilmo….
0
8
0
RT @tompowles1: The most robust data post EVP in M1 bladder cancer by Michal Sternschuss @mskcc Carboplatin/gem was the commonest regimen….
0
31
0
RT @JasonBrownMDPhD: My @caseccc colleague @shilpaonc presenting analysis of responders from EV-302 #ASCO25 . ⬆️ Duration of response to EV….
0
1
0
RT @ERPlimackMD: Devastating cut to @theNCI budget - sad to see US cancer research de-prioritized in this time of tremendous potential and….
0
7
0
RT @JasonBrownMDPhD: SURE-02 trial of SG + pembro in MIBC presented by @AndreaNecchi #ASCO25 . 🔪 Included option for bladder preservation….
0
4
0
RT @JasonBrownMDPhD: Tour de force discussion of results of CLONEVO IIT by @FaltasLab #ASCO25 . 💊 Abemaciclib with 31% downstaging rate is….
0
5
0
RT @ALLIANCE_org: @MattGalsky @IcahnMountSinai leads @ALLIANCE_org A032103 (MODERN) to test the role of DNA released from tumor cells into….
0
2
0
Our Rochester team was honored to participate in the #BCANWalk to raise awareness for #BladderCancer & support the amazing work of @BladderCancerUS. Wonderful to be part of a national effort to bring all patients an end to bladder cancer. #DrBillTabayoyong @WilmotCancer @UR_Med
2
1
9
RT @tompowles1: At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better….
0
74
0
RT @FaltasLab: Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 @ASCO! 🏢Arie Crown Theater on….
0
30
0
RT @RepGregMurphy: Great to meet with @BladderCancerUS to discuss my Bladder Cancer Awareness Bill! . As a urologist, I’m incredibly gratef….
0
6
0
RT @BladderCancerUS: This #MothersDay, let's remember that while 3 in 4 bladder cancer patients are male, women have worse outcomes at ever….
0
4
0
RT @sonpavde: #bladdercancer systemic #immunotherapy biomarker paper in @jitcancer @sitcancer: Pre-emptive identification of patients at h….
0
1
0
RT @LiangChengMD: May 2025 Marks Bladder Cancer Awareness Month - a time to renew our global commitment to raising awareness, breaking barr….
0
10
0
RT @DiMariaJiang: Thank you @ASCO daily news for the opportunity to share our (@kalasri3) thoughts on NIAGARA: NAC + periop durva for #MIBC….
dailynews.ascopubs.org
The phase 3 NIAGARA trial, which evaluated perioperative durvalumab combined with cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC), showed significantly improved...
0
1
0